DreaMed Diabetes received FDA 510(k) clearance for MODI, a mobile software tool that uses continuous glucose monitoring (CGM) data to generate insulin dosing recommendations for people with Type 2 diabetes requiring both basal insulin and fast-acting injections. The clearance advances a CGM-driven insulin automation pathway that can reduce manual dosing decisions while keeping clinicians and patients in control through software guidance.